Want to see TSE:AIDR full AI Analyst Report?
Top Page
Rocket Doctor AI
(AIDR)
Select Model
Select Model
Rating:44Neutral
Price Target:
C$0.50
▼(-17.38% Downside)
Action:Reiterated
Date:10/16/26
The score is primarily held down by weak financial performance: large ongoing losses, negative margins, persistent cash burn, and a deteriorated balance sheet with higher leverage, despite strong revenue growth from a small base. Technicals add further pressure with the stock trading below all major moving averages and negative momentum. Valuation provides limited support because the company is unprofitable (negative P/E) and no dividend yield is available.
Positive Factors
Rapid Revenue Scaling
Revenue is scaling rapidly from a small base, indicating growing adoption of the company’s healthcare technology and virtual-care offering. Continued top-line expansion could improve operating leverage over time if growth becomes large enough to absorb the current cost structure.
Negative Factors
Persistent Large Losses
The company remains deeply unprofitable despite strong revenue growth, showing that its current revenue base does not yet cover operating costs. Persistent large losses can constrain reinvestment, require external funding, and delay the point at which growth translates into sustainable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid Revenue Scaling
Revenue is scaling rapidly from a small base, indicating growing adoption of the company’s healthcare technology and virtual-care offering. Continued top-line expansion could improve operating leverage over time if growth becomes large enough to absorb the current cost structure.
Read all positive factors
Rocket Doctor AI (AIDR) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$46.58M
Dividend YieldN/A
Average Volume (3M)86.31K
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue Growth415.06%
EPS Growth-54.80%
CountryCA
Employees3
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.27
Shares Outstanding101,262,250
10 Day Avg. Volume106,517
30 Day Avg. Volume86,314
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)15.03
Price to Sales (P/S)30.35
P/FCF Ratio-8.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$1.26Price Target Upside106.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.13
Revenue Forecast (FY)C$4.16M
Rocket Doctor AI Business Overview & Revenue Model
Company Description
Rocket Doctor AI Inc., based in Vancouver, Canada, specializes in delivering personalized healthcare information services across the Canadian market. The company develops a mobile application crafted to help users assess their symptoms and effecti...
Rocket Doctor AI Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.70M | 1.74M | 10.99K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -8.24K | -6.03M | 10.99K | 0.00 | -377.28K | -656.40K |
| EBITDA | -19.35M | -14.03M | -7.52M | -2.33M | 0.00 | 0.00 |
| Net Income | -22.17M | -15.69M | -7.55M | -3.72M | -3.80M | -13.86M |
Balance Sheet | ||||||
| Total Assets | 10.18M | 10.64M | 1.28M | 739.31K | 13.67K | 942.51K |
| Cash, Cash Equivalents and Short-Term Investments | 947.65K | 641.78K | 1.23M | 715.53K | 2.50K | 916.75K |
| Total Debt | 1.20M | 415.64K | 152.00K | 584.79K | 566.28K | 0.00 |
| Total Liabilities | 9.82M | 7.13M | 486.43K | 1.48M | 2.20M | 832.62K |
| Stockholders Equity | 359.57K | 3.51M | 792.77K | -738.05K | -2.19M | 109.90K |
Cash Flow | ||||||
| Free Cash Flow | -10.03M | -6.56M | -4.44M | -740.08K | -1.46M | -6.29M |
| Operating Cash Flow | -10.00M | -6.55M | -4.44M | -740.08K | -1.46M | -6.29M |
| Investing Cash Flow | -35.38K | -1.35M | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 11.00M | 7.34M | 4.97M | 1.45M | 540.62K | 6.94M |
Rocket Doctor AI Technical Analysis
Negative
0.61
Price Trends
0.56
Negative
0.59
Negative
0.62
Negative
Market Momentum
-0.03
Positive
31.00
Neutral
19.17
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:AIDR, the sentiment is Negative. The current price of 0.61 is above the 20-day moving average (MA) of 0.52, above the 50-day MA of 0.56, and below the 200-day MA of 0.62, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 31.00 is Neutral, neither overbought nor oversold. The STOCH value of 19.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:AIDR.
Rocket Doctor AI Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | C$477.51M | 63.49 | 2.79% | ― | 53.79% | 29.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | C$2.89M | -16.67 | -49.83% | ― | -100.00% | 42.39% | |
45 Neutral | C$5.18M | -1.59 | 355.56% | ― | 614.03% | 51.97% | |
44 Neutral | C$46.58M | -1.71 | -444.52% | ― | 415.06% | -54.80% | |
43 Neutral | C$43.95M | -8.84 | 9999.00% | ― | -36.92% | 13.03% | |
42 Neutral | C$3.95M | -1.94 | 739.84% | ― | ― | -28.35% |
* Healthcare Sector Average
TSE:AIDR
Rocket Doctor AI
0.46
-0.40
-46.51%
TSE:ADK
Diagnos
0.37
0.02
4.29%
TSE:VHI
Vitalhub
7.53
-3.50
-31.73%
TSE:NDAT
nDatalyze Corp
0.07
0.06
366.67%
TSE:UDOC
UniDoc Health Corp
0.06
-0.13
-68.42%
TSE:DMED
DiagnaMed Holdings Corp.
0.03
-0.04
-53.85%
Rocket Doctor AI Corporate Events
Business Operations and StrategyFinancial Disclosures
Rocket Doctor AI Posts Strong Q3 Visit Growth, Signals Record Revenue
Positive
Oct 15, 2026
Rocket Doctor AI reported strong Q3 2026 operating metrics, completing 53,348 patient visits across North America, with U.S. visits jumping 56% quarter-over-quarter and Canadian visits rising 24% year-over-year. The company also expanded U.S. clin...
Business Operations and StrategyFinancial Disclosures
Rocket Doctor AI Accelerates U.S. Expansion as Revenue Jumps 43% in Q2
Positive
Sep 3, 2026
Rocket Doctor AI reported second-quarter 2026 revenue of $734,028, up 43% year over year, as it scaled its AI-enabled virtual care platform in North America. The company’s loss widened to $6.67 million as it invested in U.S. expansion, addin...
Business Operations and Strategy
Rocket Doctor AI Grants Equity Incentives to Consultants
Positive
Aug 24, 2026
Rocket Doctor AI Inc. has granted 24,000 stock options exercisable at $0.70 per share for three years and 276,053 restricted share units to consultants of the company and its subsidiary. The equity awards, issued under existing share compensation ...
Business Operations and Strategy
Rocket Doctor AI Secures Broad Network Deal to Expand California Telehealth Access
Positive
Aug 18, 2026
Rocket Doctor AI has secured a strategic provider network agreement in California that opens access across five healthcare and insurance channels, including commercial healthcare, Medicare Advantage, workers’ compensation, auto medical and c...
Business Operations and StrategyPrivate Placements and Financing
Rocket Doctor AI Raises C$3.26 Million in Oversubscribed Convertible Debenture Financing
Positive
Aug 17, 2026
Rocket Doctor AI Inc. has closed the second tranche of an oversubscribed private placement of unsecured convertible debentures, raising C$992,000 and bringing total proceeds from the offering to C$3,261,000. The debentures carry a 12% annual inter...
Business Operations and Strategy
Rocket Doctor AI Widens In-Network Virtual Care Reach in New York
Positive
Aug 11, 2026
Rocket Doctor AI Inc. has signed a new agreement that expands in-network access to its physician-led virtual care services for more than 100,000 additional eligible Medicare Advantage PPO and commercial health plan members in the New York City met...
Business Operations and StrategyPrivate Placements and Financing
Rocket Doctor AI Raises CAD $2.27 Million in Oversubscribed Debenture Financing to Fuel U.S. Expansion
Positive
Aug 6, 2026
Rocket Doctor AI Inc., a Vancouver-based digital health and AI technology firm, provides physician-built, AI-enabled tools and platforms that support virtual and hybrid medical practices. Its Global Library of Medicine and digital marketplace empo...
Business Operations and Strategy
Rocket Doctor AI taps B2i Digital to boost U.S. investor reach
Positive
Aug 5, 2026
Rocket Doctor AI has engaged B2i Digital to provide investor-focused digital marketing advisory services, including a featured company profile, paid digital campaigns and content distribution across major social media, email and financial communic...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.